- POLB 001 US Patent Update
- Director/PDMR Shareholding
- Director Share Purchase
- Board Role Change and Launch of EIP
- Market Opportunity for POLB 001 for CRS
- Further data shows POLB001 potential in cancer CRS
- RSV AI Drug Candidate Analysis Update
- POLB 001 Data Presented at ASH
- Directorate Change
- Immunomodulator II patent granted in Japan
More ▼
Key statistics
As of last trade Poolbeg Pharma PLC (POLB:LSE) traded at 11.76, -2.78% below its 52-week high of 12.10, set on Feb 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.30 |
Low | 11.30 |
Bid | 11.50 |
Offer | 11.80 |
Previous close | 11.50 |
Average volume | 1.66m |
---|---|
Shares outstanding | 500.00m |
Free float | 392.51m |
P/E (TTM) | -- |
Market cap | 57.50m GBP |
EPS (TTM) | -0.0098 GBP |
Data delayed at least 20 minutes, as of Apr 25 2024 10:23 BST.
More ▼